How much revenue did BioLine RX generate this year?
BioLine RX has achieved a revenue of 4.8 M USD this year.
BioLine RX Revenue 2024
BioLine RX Revenue
4.8 M USD
Ticker
BLRX.TA
ISIN
IL0011015182
In 2024, BioLine RX's sales reached 4.8 M USD, a 0% difference from the 0 USD sales recorded in the previous year.
The BioLine RX Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 4.8 | 23,08 |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | - | - |
| 2013 | - | - |
| 2012 | - | - |
| 2011 | - | - |
| 2010 | 30.33 | 77,38 |
| 2009 | 16.3 | 64,60 |
| 2008 | - | - |
| 2007 | - | - |
| 2006 | - | - |
| 2005 | - | - |
| 2004 | - | - |
BioLine RX Revenue, EBIT, Net Income IL0011015182 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BioLine RX, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioLine RX from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioLine RX’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BioLine RX. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BioLine RX’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BioLine RX’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioLine RX’s growth potential.
BioLine RX Revenue, EBIT and net profit per share
| Date | BioLine RX Revenue | BioLine RX EBIT | BioLine RX Net Income |
|---|---|---|---|
| 2023 | 4.8 M undefined | -42.99 M undefined | -60.61 M undefined |
| 2022 | 0 undefined | -29.16 M undefined | -24.95 M undefined |
| 2021 | 0 undefined | -24.78 M undefined | -27.05 M undefined |
| 2020 | 0 undefined | -22.93 M undefined | -30.02 M undefined |
| 2019 | 0 undefined | -28.11 M undefined | -25.45 M undefined |
| 2018 | 0 undefined | -25.61 M undefined | -22.96 M undefined |
| 2017 | 0 undefined | -25.24 M undefined | -24.35 M undefined |
| 2016 | 0 undefined | -16.51 M undefined | -15.84 M undefined |
| 2015 | 0 undefined | -16.2 M undefined | -14.4 M undefined |
| 2014 | 0 undefined | -17.16 M undefined | -11.09 M undefined |
| 2013 | 0 undefined | -16.99 M undefined | -17.04 M undefined |
| 2012 | 0 undefined | -21.19 M undefined | -19.81 M undefined |
| 2011 | 0 undefined | -16.41 M undefined | -14.04 M undefined |
| 2010 | 30.33 M undefined | 3.52 M undefined | 1.99 M undefined |
| 2009 | 16.3 M undefined | -16.14 M undefined | -15.69 M undefined |
| 2008 | 0 undefined | -33.31 M undefined | -32.08 M undefined |
| 2007 | 0 undefined | -21.8 M undefined | -14.48 M undefined |
| 2006 | 0 undefined | -13.06 M undefined | -12.93 M undefined |
| 2005 | 0 undefined | -6.86 M undefined | -6.31 M undefined |
| 2004 | 0 undefined | -2.25 M undefined | -2.46 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -2.25 M USD | -2.46 M USD |
| 2005 | 0 USD | -6.86 M USD | -6.31 M USD |
| 2006 | 0 USD | -13.06 M USD | -12.93 M USD |
| 2007 | 0 USD | -21.8 M USD | -14.48 M USD |
| 2008 | 0 USD | -33.31 M USD | -32.08 M USD |
| 2009 | 16.3 M USD | -16.14 M USD | -15.69 M USD |
| 2010 | 30.33 M USD | 3.52 M USD | 1.99 M USD |
| 2011 | 0 USD | -16.41 M USD | -14.04 M USD |
| 2012 | 0 USD | -21.19 M USD | -19.81 M USD |
| 2013 | 0 USD | -16.99 M USD | -17.04 M USD |
| 2014 | 0 USD | -17.16 M USD | -11.09 M USD |
| 2015 | 0 USD | -16.2 M USD | -14.4 M USD |
| 2016 | 0 USD | -16.51 M USD | -15.84 M USD |
| 2017 | 0 USD | -25.24 M USD | -24.35 M USD |
| 2018 | 0 USD | -25.61 M USD | -22.96 M USD |
| 2019 | 0 USD | -28.11 M USD | -25.45 M USD |
| 2020 | 0 USD | -22.93 M USD | -30.02 M USD |
| 2021 | 0 USD | -24.78 M USD | -27.05 M USD |
| 2022 | 0 USD | -29.16 M USD | -24.95 M USD |
| 2023 | 4.8 M USD | -42.99 M USD | -60.61 M USD |
BioLine RX stock margins IL0011015182 ·
The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BioLine RX's sales revenue. A higher gross margin percentage indicates that the BioLine RX retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BioLine RX's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BioLine RX's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioLine RX's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioLine RX. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioLine RX's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BioLine RX Margin History
| BioLine RX Gross margin | BioLine RX Profit margin | BioLine RX EBIT margin | BioLine RX Profit margin |
|---|---|---|---|
| 2023 | 23.08 % | -895.65 % | -1,262.79 % |
| 2022 | 23.08 % | 0 % | 0 % |
| 2021 | 23.08 % | 0 % | 0 % |
| 2020 | 23.08 % | 0 % | 0 % |
| 2019 | 23.08 % | 0 % | 0 % |
| 2018 | 23.08 % | 0 % | 0 % |
| 2017 | 23.08 % | 0 % | 0 % |
| 2016 | 23.08 % | 0 % | 0 % |
| 2015 | 23.08 % | 0 % | 0 % |
| 2014 | 23.08 % | 0 % | 0 % |
| 2013 | 23.08 % | 0 % | 0 % |
| 2012 | 23.08 % | 0 % | 0 % |
| 2011 | 23.08 % | 0 % | 0 % |
| 2010 | 77.38 % | 11.61 % | 6.56 % |
| 2009 | 64.6 % | -99.02 % | -96.26 % |
| 2008 | 23.08 % | 0 % | 0 % |
| 2007 | 23.08 % | 0 % | 0 % |
| 2006 | 23.08 % | 0 % | 0 % |
| 2005 | 23.08 % | 0 % | 0 % |
| 2004 | 23.08 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 23.08 % | 0 % | 0 % |
| 2005 | 23.08 % | 0 % | 0 % |
| 2006 | 23.08 % | 0 % | 0 % |
| 2007 | 23.08 % | 0 % | 0 % |
| 2008 | 23.08 % | 0 % | 0 % |
| 2009 | 64.6 % | -99.02 % | -96.26 % |
| 2010 | 77.38 % | 11.61 % | 6.56 % |
| 2011 | 23.08 % | 0 % | 0 % |
| 2012 | 23.08 % | 0 % | 0 % |
| 2013 | 23.08 % | 0 % | 0 % |
| 2014 | 23.08 % | 0 % | 0 % |
| 2015 | 23.08 % | 0 % | 0 % |
| 2016 | 23.08 % | 0 % | 0 % |
| 2017 | 23.08 % | 0 % | 0 % |
| 2018 | 23.08 % | 0 % | 0 % |
| 2019 | 23.08 % | 0 % | 0 % |
| 2020 | 23.08 % | 0 % | 0 % |
| 2021 | 23.08 % | 0 % | 0 % |
| 2022 | 23.08 % | 0 % | 0 % |
| 2023 | 23.08 % | -895.65 % | -1,262.79 % |
BioLine RX Aktienanalyse
What does BioLine RX do?
BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding BioLine RX's Sales Figures
The sales figures of BioLine RX originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing BioLine RX’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize BioLine RX's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in BioLine RX’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about BioLine RX stock
How much was the turnover of the company BioLine RX compared to the previous year?
The revenue of BioLine RX has increased by 0% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of BioLine RX?
The revenue of BioLine RX is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of BioLine RX measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of BioLine RX so important for investors?
The revenue of BioLine RX is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does BioLine RX pay?
Over the past 12 months, BioLine RX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioLine RX is expected to pay a dividend of 0 USD.
What is the dividend yield of BioLine RX?
The current dividend yield of BioLine RX is .
When does BioLine RX pay dividends?
BioLine RX pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioLine RX?
BioLine RX paid dividends every year for the past 0 years.
What is the dividend of BioLine RX?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BioLine RX located?
BioLine RX is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioLine RX kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioLine RX from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.
When did BioLine RX pay the last dividend?
The last dividend was paid out on 10/3/2024.
What was the dividend of BioLine RX in the year 2023?
In the year 2023, BioLine RX distributed 0 USD as dividends.
In which currency does BioLine RX pay out the dividend?
The dividends of BioLine RX are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioLine RX
Our stock analysis for BioLine RX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLine RX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
